Skip to content

Study to Evaluate the Impact of the Recovery Pathway on Postoperative Leght of Stay in Coronary Artery Bypass Surgery

Prospective and Randomized Study to Evaluate the Impact of the Recovery Pathway on Postoperative Leght of Stay in Coronary Artery Bypass Surgery

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06713096
Acronym
KAMAY
Enrollment
128
Registered
2024-12-03
Start date
2021-11-25
Completion date
2025-12-31
Last updated
2024-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Enhanced Recovery After Surgery, Quality Improvement

Brief summary

This randomized and prospective trial aims to evaluate the implementation of a rapid recovery protocol for coronary artery bypass grafting (CABG) in a hospital serving patients from the Brazilian Unified Health System (Sistema Único de Saúde - SUS). The study will compare outcomes between two groups: patients receiving care under the rapid recovery protocol and those following the standard institutional care. Primary Objective: Compare postoperative hospital stay between the rapid recovery group and the usual care group. Secondary Objectives: Assess morbidity and mortality between both groups. Evaluate patient satisfaction using validated tools. Analyze incremental costs associated with both approaches. Assess healthcare teams' learning progression regarding the protocol (Kirkpatrick method). Evaluate adherence to rapid recovery protocol metrics by healthcare teams. Measure changes in patient safety culture among healthcare professionals. Hypothesis: The null hypothesis assumes no difference in hospital stay between the two groups. The alternative hypothesis suggests that the rapid recovery protocol will reduce hospital stay compared to the standard care. Previous findings from Mejia et al. (2022) indicated a 40% reduction in postoperative hospital stay (from 13 to 7.8 days) for cardiac surgery patients under a rapid recovery protocol at the Heart Institute (InCor HCFMUSP). This trial will provide critical insights into the applicability of enhanced recovery after surgery (ERAS) principles in cardiac surgery within the context of public healthcare, aiming to improve outcomes and optimize resource use.

Interventions

BEHAVIORALTempos Certos protocol

Improve the enhanced recovery by using the Tempos Certos Protocol by the multiprofissional team , using interventions known by science and recommended by scientists.

Sponsors

University of Sao Paulo General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Adult patients (\>18 years old) * Undergoing isolated coronary artery bypass grafting (CABG) with elective or urgent status * Signed informed consent form (ICF)

Exclusion criteria

* Emergency patients * Severe ventricular dysfunction (ejection fraction \<30%) * Renal impairment (creatinine clearance \<30 mL/min) * Atrial fibrillation or need for oral anticoagulation * Moderate-to-severe anemia (hematocrit \<32%) * STS risk score \>4% * Patient and/or family disagreement with the protocol * Failure to sign the informed consent form

Design outcomes

Primary

MeasureTime frameDescription
Postoperative hospital stayFrom admission to the intensive care unit until hospital discharge (an average of 14 days of leght of hospital stay)Count of time between admission to the intensive care unit and hospital discharge (in hours and days).

Secondary

MeasureTime frameDescription
Number of participants with cardiac reoperation, deep sternal wound infection/mediastinitis, stroke, prolonged ventilation, renal failure, or death within 30 days after surgery (morbimortality)Hospital stay to 30 days after hospital discharge (an average of 14 days of leght of hospital stay)Incidence of key morbidities and mortality, including cardiac reoperation, deep sternal wound infection/mediastinitis, stroke, prolonged ventilation, renal failure, and death.
Patient-reported Patient-reported quality of life (SF-36)Before surgery and 30 days after hospital discharge (an average of 14 days of leght of hospital stay)Quality of life assessed by SF-36 survey before surgery and 30 days after hospital discharge. Scores range from 0 to 100, with higher scores indicating better quality of life.
Patient-reported Anxiety and depression (HADS)Intervention group: Before surgery, at hospital discharge, and 30 days after hospital discharge. Control group: Before surgery and 30 days after hospital discharge (an average of 14 days of leght of hospital stay)Assessment of anxiety and depression using the Hospital Anxiety and Depression Scale (HADS). Scores range from 0 to 21 for both anxiety and depression subscales, with higher scores indicating greater levels of anxiety or depression.
Patient experience (HCAHPS)Between 3 and 30 days after hospital discharge (an average of 14 days of leght of hospital stay).Assessment of patient experience using the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey.
Incremental Costs Assessed Using Micro-Costing AnalysisFrom hospital admission through the postoperative period, including readmissions up to 30 days after discharge.Incremental costs assessed through a detailed micro-costing analysis of preoperative, intraoperative, and postoperative phases. Costs will include hospital stay (ward and intensive care unit), multiprofessional care, medications (including blood transfusion), surgical room costs (surgery time and equipment), operational equipment, consumables, imaging exams, and medical supplies. Costs associated with readmissions within 30 days after discharge will also be included.

Other

MeasureTime frameDescription
Kirkpatrick Evaluation ModelLevels 1 and 2: Before training, after training (5 pilot cases conducted in year 1), and at study conclusion. Level 3: After pilot cases (year 1) and study conclusion. Level 4: At study conclusion.Assessment of healthcare professionals' training and behavioral changes using the four levels of the Kirkpatrick Evaluation Model: Level 1 (Reaction): Assessed participant satisfaction/motivation via a 5-question Likert scale survey (3-point scale: strongly agree, partially agree, strongly disagree) at three time points: before the project, after training and five pilot cases, and after completing randomized recruitment. Level 2 (Learning): Evaluated knowledge improvement through a questionnaire (7 multiple-choice questions and 3 true/false questions) at the same time points as Level 1. Level 3 (Behavior): Measured adherence to protocol metrics after five pilot cases and at the conclusion of randomized recruitment. Minimum adherence target: 70%. Level 4 (Results): Assessed project outcomes, specifically a 40% reduction in postoperative hospital stay with 70% protocol adherence at the end of randomized recruitment.
Patient Safety Culture (HSPSC)Before training, after training and experience with five pilot cases (first year of the study), and at the conclusion of randomized recruitment.Evaluation of patient safety culture among healthcare professionals using the Hospital Survey on Patient Safety Culture (HSPSC), comprising 42 items across 12 dimensions: Teamwork within units Organizational learning/continuous improvement Supervisor/manager expectations/actions promoting safety Hospital management support for patient safety Overall perception of safety Feedback and communication about error Communication openness Frequency of event reporting Teamwork across units Staffing Handoffs and transitions Non-punitive response to errors Responses will be collected on a 5-point Likert scale ranging from strongly disagree or never to strongly agree or always. Scores will be classified into three categories: Strengthened areas (≥75% positive responses) Potential improvement areas (\<75% and \>50% positive responses) Fragile areas (≤50% positive responses)

Countries

Brazil

Contacts

Primary ContactOmar A V Mejia, md, PhD
omarvmejia@gmail.com555+(11) 2661-5014

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026